Page last updated: 2024-08-21

arsenic trioxide and Astroblastoma

arsenic trioxide has been researched along with Astroblastoma in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Alt, F; Backes, N; Bender, H; Brockmann, MA; Burhenne, J; Faber, J; Filipski, K; Fresnais, M; Glaser, M; Harter, PN; Huprich, S; Lehmann, N; Neu, MA; Paret, C; Pietsch, T; Roth, L; Russo, A; Seidmann, L; Sommer, C; Wagner, W; Wingerter, A	1
El Malki, K; Faber, J; Gerhold-Ay, A; Kron, B; Lehmann, N; Neu, MA; Paret, C; Pietsch, T; Russo, A; Seidmann, L; Sommer, C; Theruvath, J; Wagner, W; Wingerter, A	1

Other Studies

2 other study(ies) available for arsenic trioxide and Astroblastoma

Article	Year
Ceritinib-Induced Regression of an Insulin-Like Growth Factor-Driven Neuroepithelial Brain Tumor. International journal of molecular sciences, 2019, Aug-30, Volume: 20, Issue:17 Topics: Adult; Arsenic Trioxide; Base Sequence; Brain; Brain Neoplasms; Cell Line, Tumor; Child, Preschool; Chromosome Aberrations; DNA Methylation; Female; Germ-Line Mutation; Humans; Insulin-Like Growth Factor I; Molecular Targeted Therapy; Neoplasms, Neuroepithelial; Principal Component Analysis; Pyrimidines; Receptor, Notch1; Sulfones; Transcriptome; Tumor Suppressor Protein p53	2019
Activation of the basal cell carcinoma pathway in a patient with CNS HGNET-BCOR diagnosis: consequences for personalized targeted therapy. Oncotarget, 2016, Dec-13, Volume: 7, Issue:50 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Axin Protein; Biomarkers, Tumor; Biopsy; Brain Neoplasms; Carcinoma, Basal Cell; Cell Survival; Child; DNA Mutational Analysis; Dose-Response Relationship, Drug; Genetic Predisposition to Disease; Hedgehog Proteins; Humans; Inhibitory Concentration 50; Magnetic Resonance Imaging; Male; Mutation; Neoplasms, Neuroepithelial; Oxides; Patched-1 Receptor; Phenotype; Polymorphism, Single Nucleotide; Precision Medicine; Predictive Value of Tests; Proto-Oncogene Proteins; Repressor Proteins; Smoothened Receptor; Tumor Cells, Cultured; Up-Regulation; Wnt Signaling Pathway; Zinc Finger Protein GLI1	2016

Article

Year

Ceritinib-Induced Regression of an Insulin-Like Growth Factor-Driven Neuroepithelial Brain Tumor.

International journal of molecular sciences, 2019, Aug-30, Volume: 20, Issue:17

Topics: Adult; Arsenic Trioxide; Base Sequence; Brain; Brain Neoplasms; Cell Line, Tumor; Child, Preschool; Chromosome Aberrations; DNA Methylation; Female; Germ-Line Mutation; Humans; Insulin-Like Growth Factor I; Molecular Targeted Therapy; Neoplasms, Neuroepithelial; Principal Component Analysis; Pyrimidines; Receptor, Notch1; Sulfones; Transcriptome; Tumor Suppressor Protein p53

2019

Activation of the basal cell carcinoma pathway in a patient with CNS HGNET-BCOR diagnosis: consequences for personalized targeted therapy.

Oncotarget, 2016, Dec-13, Volume: 7, Issue:50

Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Axin Protein; Biomarkers, Tumor; Biopsy; Brain Neoplasms; Carcinoma, Basal Cell; Cell Survival; Child; DNA Mutational Analysis; Dose-Response Relationship, Drug; Genetic Predisposition to Disease; Hedgehog Proteins; Humans; Inhibitory Concentration 50; Magnetic Resonance Imaging; Male; Mutation; Neoplasms, Neuroepithelial; Oxides; Patched-1 Receptor; Phenotype; Polymorphism, Single Nucleotide; Precision Medicine; Predictive Value of Tests; Proto-Oncogene Proteins; Repressor Proteins; Smoothened Receptor; Tumor Cells, Cultured; Up-Regulation; Wnt Signaling Pathway; Zinc Finger Protein GLI1

2016